Poseltinib

Poseltinib
Clinical data
Other names	HM-7122; LY 3337641
Identifiers
	IUPAC name N-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide;
CAS Number	1353552-97-2;
PubChem CID	56644522;
UNII	D01E4B1U35;
Chemical and physical data
Formula	C26H26N6O3
Molar mass	470.533 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC(NC1=CC=CC(OC2=C(OC=C3)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=N2)=C1)=O;

Poseltinib (HM71224, LY3337641) is an experimental Bruton's tyrosine kinase inhibitor for the treatment of rheumatoid arthritis. It was developed by Hanmi Pharmaceutical and licensed to Eli Lilly.[1]

Phase II clinical trials began in August 2016 in patients with rheumatoid arthritis. Additional phase II trials are planned for treatment of lupus, lupus nephritis, Sjögren's syndrome, and other immunological conditions.[2]

References

Alternative Names: HM 71224; LY 3337641. "Poseltinib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.
"Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy (NYSE:LLY)". Investor.lilly.com. 2015-03-19. Retrieved 2017-05-22.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Alternative Names: HM 71224; LY 3337641. "Poseltinib - AdisInsight". Adisinsight.springer.com. Retrieved 2017-05-22.

[2] "Lilly and Hanmi Announce an Exclusive License and Collaboration Agreement for the Development and Commercialization of an Immunological Therapy (NYSE:LLY)". Investor.lilly.com. 2015-03-19. Retrieved 2017-05-22.